Last reviewed · How we verify
Erythromycin, Azithromycin , Clarithromycin
These macrolide antibiotics inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit.
These macrolide antibiotics inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Respiratory tract infections (pneumonia, bronchitis), Skin and soft tissue infections, Sexually transmitted infections (chlamydia, gonorrhea).
At a glance
| Generic name | Erythromycin, Azithromycin , Clarithromycin |
|---|---|
| Sponsor | Baqiyatallah Medical Sciences University |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Erythromycin, azithromycin, and clarithromycin are macrolide antibiotics that bind reversibly to the bacterial 50S ribosomal subunit, blocking peptide translocation and inhibiting protein synthesis. This bacteriostatic action prevents bacterial growth and reproduction. They are effective against a broad spectrum of gram-positive and some gram-negative bacteria, as well as atypical organisms.
Approved indications
- Respiratory tract infections (pneumonia, bronchitis)
- Skin and soft tissue infections
- Sexually transmitted infections (chlamydia, gonorrhea)
- Otitis media
- Streptococcal pharyngitis
- Mycobacterial infections (MAC prophylaxis in HIV)
Common side effects
- Gastrointestinal disturbance (nausea, vomiting, diarrhea)
- Abdominal pain
- Headache
- QT prolongation
- Hepatotoxicity
- Allergic reactions
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections (PHASE3)
- Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes (NA)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
- Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: